# Ventilator-Associated Pneumonia

Ventilator-associated pneumonia requires prompt empiric treatment when clinical suspicion is high, while respiratory sampling, serial reassessment, and culture-directed de-escalation limit overtreatment in a syndrome with imperfect diagnostic tests.

**Clinical question:** How should clinicians diagnose, treat, reassess, and prevent suspected ventilator-associated pneumonia in mechanically ventilated adults?

Updated: 2026-08-24T16:14:33.991194+00:00

## What matters in practice
- Treat VAP as a clinical syndrome arising more than 48 hours after intubation, but do not equate a positive airway culture with pneumonia because clinical diagnosis and microbiologic reference standards are imperfect. [8][10][18]
- Obtain a lower-respiratory specimen promptly when VAP is suspected; semiquantitative endotracheal aspirate cultures are a practical option, and bronchoscopic BAL has not shown better mortality, ventilator-duration, or ICU-length-of-stay outcomes. [10]
- Use culture results and clinical trajectory to narrow or stop empiric antibiotics; antibiotic overuse in suspected VAP promotes resistance and avoidable toxicity. [24]
- Avoid tigecycline for hospital-acquired or ventilator-associated pneumonia when alternatives are suitable: an HAP/VAP trial failed to establish efficacy, and mortality was higher in ventilator-associated pneumonia. [1][2]

## Act on suspected VAP while testing competing explanations

VAP begins more than 48 hours after invasive ventilation.

New or worsening oxygenation impairment, purulent endotracheal secretions, fever or leukocytosis, and a new or progressive infiltrate should trigger a focused VAP assessment, but no single clinical feature reliably establishes the diagnosis. Clinical diagnosis remains inaccurate, and approximately one quarter to one third of patients with clinically suspected VAP may have true infection. [7][8]

At the bedside, first identify instability requiring immediate management: escalating oxygen or ventilator support, shock, or rapidly progressive respiratory failure should prompt prompt pneumonia-directed antimicrobial therapy after respiratory sampling when this does not delay treatment. Simultaneously reassess noninfectious and alternative infectious causes of infiltrates and hypoxemia, because false-positive VAP diagnoses expose patients to unnecessary antibiotic toxicity and selection of resistant organisms. [10][24]

Send a lower-respiratory specimen before or at antibiotic initiation when feasible. Endotracheal aspirate sampling is less invasive than bronchoscopic techniques; evidence comparing BAL or protected specimen brush with endotracheal aspirate has not shown reductions in mortality, ICU length of stay, or duration of mechanical ventilation. [10]
- Document the time from intubation: VAP is conventionally pneumonia arising after at least 48 hours of mechanical ventilation. [18]
- Review prior antibiotics, duration of ventilation, prior respiratory cultures, and local susceptibility data before selecting empiric coverage; later-onset VAP is more often associated with multidrug-resistant organisms, although timing alone is not determinative. [24]
- Obtain a chest radiograph to evaluate a new infiltrate in the suspected hospital-acquired pneumonia syndrome. [23]

*Sampling and diagnostic tools should support—not replace—clinical reassessment in suspected VAP. [8][10]*

| Tool | Decision value | Important limitation |
| --- | --- | --- |
| Semiquantitative endotracheal aspirate culture | Practical lower-airway microbiology approach; guidelines discussed in contemporary review favor semiquantitative cultures because they are faster and require fewer laboratory resources than quantitative cultures. [10] | Airway colonization can yield false-positive results; interpret with clinical course. [10] |
| Bronchoalveolar lavage | May provide quantitative culture and cell differential data when bronchoscopy is otherwise indicated or diagnostic uncertainty remains high. [6][10] | Compared with endotracheal aspirate, BAL has not reduced mortality, ventilation duration, or ICU stay. [10] |
| Protected specimen brush | Alternative bronchoscopic sampling method. Reported sensitivity is 61.4% and specificity 76.5%, with wide confidence intervals. [10] | No accepted universal diagnostic reference standard; performance estimates are uncertain. [10] |
| Clinical Pulmonary Infection Score | A score greater than 6 has reported sensitivity of 73.8% and specificity of 66.4% for VAP. [10] | Accuracy varies with reference standard and CPIS modifications; do not use as the sole basis for treatment. [10] |

## Use cultures and trajectory to distinguish infection from colonization

A respiratory isolate requires clinical context before it becomes a treatment target.

Interpret respiratory cultures against the full trajectory: changing oxygenation, secretion burden, leukocyte count, chest radiography, and response to therapy are components used in a Day 10 clinical-cure framework. Persistent or recurrent deterioration despite active therapy should prompt reassessment for an untreated pathogen, inadequate drug exposure, a nonpulmonary source, or a noninfectious pulmonary process rather than automatic antibiotic extension. [6]

Quantitative microbiology can refine probability but does not resolve diagnostic uncertainty. In one ICU research definition, bacterial pneumonia required a positive quantitative culture above 100 CFU/mL, bacterial PCR from BAL fluid, or a positive urine antigen in the appropriate clinical setting; this is a study definition, not a universal treatment threshold. [11]

BAL neutrophil percentage, quantitative culture burden, and pathogen genomic load are being evaluated as predictors of VAP treatment failure, but these biomarkers should not yet replace standard clinical and microbiologic assessment. [5][6]
- If cultures identify an organism, narrow therapy to the susceptible pathogen and reassess whether the respiratory syndrome remains consistent with pneumonia. [24]
- If microbiology is unrevealing and clinical features improve, reassess the need for continued pneumonia-directed antibiotics rather than treating airway colonization. [6][24]
- Do not use procalcitonin alone to diagnose VAP; its diagnostic role has been studied, but clinical diagnosis remains problematic and no definitive biomarker standard is established. [8][12]

## Start empiric therapy for high-probability VAP, then de-escalate

The core treatment sequence is adequate initial therapy followed by culture-directed narrowing.

For a patient with high clinical probability of VAP, select empiric antibiotics using the local ICU antibiogram, prior respiratory isolates, recent antibiotic exposure, and risk for multidrug-resistant organisms. Early VAP, defined in one review as occurring within 4 days of intubation, is more often attributed to antibiotic-susceptible pathogens, whereas VAP emerging after 4 days is more often associated with multidrug-resistant bacteria; use this as a risk modifier rather than a stand-alone rule. [24]

Once microbiology and susceptibility data return, de-escalate to the narrowest active regimen and align treatment duration with clinical and bacteriologic progress. This limits resistance, adverse effects, and toxicity from empiric broad-spectrum therapy. [24]

Do not select tigecycline for VAP when suitable alternatives exist. The FDA label reports that a hospital-acquired pneumonia trial, including ventilator-associated pneumonia, failed to demonstrate efficacy; among ventilator-associated pneumonia patients, mortality was 19.1% with tigecycline versus 12.3% with comparator treatment. [1][2]
- If tigecycline is being considered for another labeled indication, standard adult dosing is 100 mg IV once followed by 50 mg IV every 12 hours, infused over 30 to 60 minutes; this dosing does not overcome its unfavorable VAP evidence. [2]
- In severe hepatic impairment (Child-Pugh C), the tigecycline label specifies 100 mg initially followed by 25 mg every 12 hours, with caution and monitoring of treatment response. [1]
- Avoid tigecycline in patients with known tetracycline-class hypersensitivity because life-threatening anaphylactic reactions have been reported. [2]

*Antibiotic decisions in suspected VAP should be revisited when respiratory microbiology and clinical response are available. [24]*

| Treatment phase | Required decision | Avoidable error |
| --- | --- | --- |
| Initial suspicion | Obtain a respiratory specimen and begin empiric therapy promptly in clinically high-probability or unstable VAP, guided by individual resistance risk and local susceptibility patterns. [24] | Delaying treatment in a deteriorating patient or using a fixed regimen without local resistance context. [24] |
| Microbiology review | Target recovered susceptible pathogens and reassess whether the isolate represents infection rather than colonization. [10][24] | Continuing broad empiric therapy despite culture and clinical data supporting narrowing. [24] |
| Clinical improvement | Use improvement in oxygenation, secretions, leukocyte count, and radiography with microbiologic information to decide whether to stop pneumonia-directed therapy. [6] | Extending therapy solely because a ventilated airway culture remains positive. [6][10] |
| Tigecycline consideration | Choose an alternative when available for VAP. [1][2] | Using tigecycline as a routine VAP regimen despite failed efficacy and higher mortality in the VAP subgroup. [1][2] |

## Define response and investigate failure rather than escalating reflexively

Trend objective respiratory and systemic measures after therapy begins.

Monitor oxygenation and ventilator requirements, endotracheal secretion burden, white blood cell count, and chest radiography after initiating treatment. A clinical-cure framework at Day 10 requires survival without planned comfort-only care plus either discontinuation of pneumonia antibiotics without recurrence within 48 hours or continued therapy with stable or improved pneumonia signs and symptoms. [6]

Failure to stabilize or improve should trigger a diagnostic reset: review whether the recovered organism is susceptible to the selected regimen, whether the respiratory sample represents colonization, and whether another pulmonary or extrapulmonary process better explains the deterioration. The absence of a universally accepted VAP reference standard means discordance between clinical and microbiologic findings is common. [10]

Escalating to repeat BAL, quantitative culture, or advanced biomarker testing should be selective. Quantitative cultures have not demonstrated improvement in mortality, ICU stay, mechanical-ventilation duration, or antibiotic-change rates compared with qualitative cultures, so invasive sampling is most useful when it is expected to alter a specific management decision. [10]
- Record antibiotic stop dates and reassess daily for de-escalation or discontinuation. [24]
- If antibiotics are stopped, monitor for recurrence during the subsequent 48 hours as part of clinical-cure assessment. [6]
- When treatment failure is suspected, obtain targeted repeat microbiology only if the result will change antimicrobial selection or clarify an alternative diagnosis. [10]

## Reduce ventilator exposure and avoid unproven routine prophylaxis

Prevention strategies should be embedded in mechanical-ventilation care.

Apply evidence-based hospital practices intended to prevent pneumonia in ventilated patients and reassess the continuing need for invasive ventilation, because VAP is defined by its occurrence after prolonged mechanical ventilation. Current guideline-based prevention practices are used in hospitalized patients, although specific bundle components should follow institutional protocols. [3][18]

Inhaled amikacin has been studied as a preventive intervention: among patients mechanically ventilated for at least 3 days, a subsequent 3-day course reduced the burden of VAP. This finding supports consideration only within a protocolized prevention strategy; it does not establish inhaled amikacin as treatment for established VAP or replace standard prevention practices. [4]

Do not confuse prevention with indiscriminate antimicrobial exposure. Antibiotic overuse in suspected VAP contributes to resistance and toxicity; prevention programs should preserve diagnostic stewardship and prompt de-escalation when VAP is not confirmed clinically. [24]
- Track VAP events and prevention-process adherence as ICU quality measures, recognizing that VAP rates are commonly used as quality indicators. [16]
- Use local prevention policies that address secretion drainage and bacterial colonization, two targets emphasized in preventive-strategy discussions. [17]

## References
1. 211158Orig1s000 | FDA - accessdata.fda.gov — www.accessdata.fda.gov — https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211158Orig1s000Lbl.pdf
2. [PDF] 4139875 This label may not be the latest approved by FDA. For ... — www.accessdata.fda.gov — https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/205645s001lbl.pdf
3. Health Care–Associated Infections in U.S. Hospitals, 2023 ... — www.nejm.org — https://www.nejm.org/doi/full/10.1056/NEJMoa2510881
4. Inhaled Amikacin to Prevent Ventilator-Associated ... — www.nejm.org — https://www.nejm.org/doi/full/10.1056/NEJMoa2310307
5. Ventilator-associated pneumonia biomarker evaluation ... — bmjopen.bmj.com — https://bmjopen.bmj.com/content/15/9/e110019
6. associated pneumonia biomarker evaluation (VIBE) study: ... — bmjopen.bmj.com — https://bmjopen.bmj.com/content/bmjopen/15/9/e110019.full.pdf
7. Diagnostic importance of pulmonary interleukin-1 ... - Thorax — thorax.bmj.com — https://thorax.bmj.com/content/thoraxjnl/early/2009/10/12/thx.2009.122291.full.pdf
8. Diagnostic importance of pulmonary interleukin-1β and ... — thorax.bmj.com — https://thorax.bmj.com/content/65/3/201
9. Diagnostic importance of pulmonary interleukin-1b ... - Thorax — thorax.bmj.com — https://thorax.bmj.com/content/thoraxjnl/65/3/201.full.pdf
10. Ventilator-associated pneumonia: pathobiological heterogeneity and diagnostic challenges | Nature Communications — www.nature.com — https://www.nature.com/articles/s41467-024-50805-z
11. Circuits between infected macrophages and T cells in SARS-CoV-2 pneumonia | Nature — www.nature.com — https://www.nature.com/articles/s41586-020-03148-w
12. Pneumonia | Nature Reviews Disease Primers — www.nature.com — https://www.nature.com/articles/s41572-021-00259-0
13. Longitudinal multicompartment characterization of host ... — www.nature.com — https://www.nature.com/articles/s41467-024-48819-8
14. Pneumonia after Solid Organ Transplantation — journals.lww.com — https://journals.lww.com/00019574-202604000-00003
15. Hospital antibiotic stewardship — journals.lww.com — https://journals.lww.com/co-infectiousdiseases/fulltext/2008/08000/hospital_antibiotic_stewardship.3.aspx
16. The Centers for Disease Control and Prevention's... — journals.lww.com — https://journals.lww.com/ccmjournal/fulltext/2015/11000/the_centers_for_disease_control_and_prevention_s.22.aspx?Ppt=Article%7Cccmjournal%3A2015%3A11000%3A00022%7C10.1097%2Fccm.0000000000001261%7C
17. Ventilator Associated Pneumonia — journals.lww.com — https://journals.lww.com/jpcr/fulltext/2019/06040/ventilator_associated_pneumonia.8.aspx
18. Ventilator-Associated Pneumonia - an overview — www.sciencedirect.com — https://www.sciencedirect.com/topics/medicine-and-dentistry/ventilator-associated-pneumonia
19. Consensus document on controversial issues for the ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S1201971210023660
20. European Journal of Pharmaceutical Sciences — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0928098719301952
21. Management of Non-Ventilated hospital acquired pneumonia — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S2590170224000104
22. Prevention of ventilator-associated pneumonia in the ... — www.jtcvs.org — https://www.jtcvs.org/article/S0022-5223(14)01224-0/pdf
23. antimicrobial prescribing - Pneumonia (hospital- acquired) — www.nice.org.uk — https://www.nice.org.uk/guidance/ng250/evidence/evidence-review-antimicrobial-prescribing-guideline-for-hospital-acquired-pneumonia-september-pdf-15432555423
24. Ventilator-associated pneumonia in the ICU - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC4056625

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.